Unknown

Dataset Information

0

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target.


ABSTRACT: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy for which there is still no effective therapy. In order to identify genetic alterations useful for a new treatment design, we used whole-exome sequencing to analyze 14 BPDCN patients and the patient-derived CAL-1 cell line. The functional enrichment analysis of mutational data reported the epigenetic regulatory program to be the most significantly undermined (P<0.0001). In particular, twenty-five epigenetic modifiers were found mutated (e.g. ASXL1, TET2, SUZ12, ARID1A, PHF2, CHD8); ASXL1 was the most frequently affected (28.6% of cases). To evaluate the impact of the identified epigenetic mutations at the gene-expression and Histone H3 lysine 27 trimethylation/acetylation levels, we performed additional RNA and pathology tissue-chromatin immunoprecipitation sequencing experiments. The patients displayed enrichment in gene signatures regulated by methylation and modifiable by decitabine administration, shared common H3K27-acetylated regions, and had a set of cell-cycle genes aberrantly up-regulated and marked by promoter acetylation. Collectively, the integration of sequencing data showed the potential of a therapy based on epigenetic agents. Through the adoption of a preclinical BPDCN mouse model, established by CAL-1 cell line xenografting, we demonstrated the efficacy of the combination of the epigenetic drugs 5'-azacytidine and decitabine in controlling disease progression in vivo.

SUBMITTER: Sapienza MR 

PROVIDER: S-EPMC6442957 | BioStudies | 2019-01-01

SECONDARY ACCESSION(S): GSE62014

REPOSITORIES: biostudies

Similar Datasets

2018-02-06 | GSE110140 | GEO
2014-01-01 | S-EPMC4294271 | BioStudies
2016-11-15 | GSE75650 | GEO
2016-01-01 | S-EPMC5043425 | BioStudies
2020-01-01 | S-EPMC7079160 | BioStudies
2016-11-15 | GSE84471 | GEO
2017-01-01 | S-EPMC6467341 | BioStudies
2019-01-01 | S-EPMC6562447 | BioStudies
2016-11-15 | GSE84623 | GEO
1000-01-01 | S-EPMC4171639 | BioStudies